Annual report for Anuh Pharma Ltd. for FY-2022
14-05-2022
ANUH PHARMA LTD. - 506260 - Intimation Pursuant To Regulation 31A(8)(A) Of The SEBI Listing Regulations About Request Received For Reclassification Of Certain Persons From ''Promoter/ Promoter Group'' To ''Public'' Category''.
Please find attached the request letters dated May 12, 2022, received from certain Promoters/ Promoter Group of the Company seeking reclassification of their shareholding from ''Promoters/ Promoter Group'' category to ''Public'' category.13-05-2022
ANUH PHARMA LTD. - 506260 - Corporate Action-Board to consider Dividend
Anuh Pharma Ltd. has informed BSE that a meeting of the Board of Directors of the Company is scheduled to be held on May 14, 2022, inter alia, to consider and approve the audited financial results for the quarter and year ended March 31, 2022 and to consider recommendation of dividend, if any, amongst other routine matters.07-05-2022
ANUH PHARMA LTD. - 506260 - Board Meeting Intimation for Board Meeting Intimation For Prior Intimation Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
ANUH PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2022 ,inter alia, to consider and approve Pursuant to the provisions of Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Meeting of the Board of Directors of the Company is scheduled to be held on Saturday, 14th May, 2022, inter alia: 1) To consider and approve Audited Financial Results of the Company for the quarter & year ended 31st March, 2022; and 2) To consider and recommend Final Dividend, if any, for the financial year 2021-22.07-05-2022
ANUH PHARMA LTD. - 506260 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayANUH PHARMA LTD. 2CINL24230MH1960PLC011586 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: BharatKumar Becharbhai Gangani Designation: Company Secretary & Compliance Officer EmailId: [email protected] Name of the Chief Financial Officer: DARSHAN RAMPARIYA Designation: Chief Financial Officer EmailId: [email protected] Date: 29/04/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.29-04-2022
ANUH PHARMA LTD. - 506260 - Certificate Under Regulation 40(9) Of The SEBI (LODR) Regulations, 2015 For The Year Ended 31St March, 2022.
Pursuant the provisions of Regulation 40(10) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith the Certificate dated 8th April, 2022 for the year ended 31st March, 2022 issued in accordance with the Regulation 40(9) of the aforesaid Regulations by Sanjay Doshi and Associates, Company Secretaries.11-04-2022
ANUH PHARMA LTD. - 506260 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Pursuant to the provisions of Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants), Regulations, 2018, please find attached herewith the copy of the certificate issued by M/s Bigshare Services Pvt. Ltd., the Registrar and Share Transfer Agent of the Company for the quarter ended 31st March, 2022. Kindly acknowledge the receipt and take the same on record.06-04-2022
ANUH PHARMA LTD. - 506260 - Statement Of Investor Complaints For The Quarter Ended March 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- Bharat GanganiDesignation :- Company Secretary and Compliance Officer06-04-2022
ANUH PHARMA LTD. - 506260 - UPDATION OF PAN, KYC, NOMINATION, BANK DETAILS, ETC.
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that based on the recommendation of Audit Committee, the Board of Directors of the Company at their meeting held on 21st March, 2022, Considered, Reviewed and Approved Modifications to the policy on Materiality of Related Party Transactions and on Dealing with Related Party Transactions. The same shall also be placed on the website of the Company.28-03-2022
ANUH PHARMA LTD. - 506260 - Closure of Trading Window
Pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and in compliance with the Company's Code of Conduct for prevention of Insider Trading, the Trading window for dealing in the securities of the Company will be closed for the Designated Persons and their immediate relatives, from Thursday, March 31, 2022 till 48 hours after the declaration of Audited Financial Results of the Company for the quarter & year ended March 31, 2022.28-03-2022